shr-1210
Showing 1 - 25 of 46
Advanced Tumors Trial (SHR-1210)
Not yet recruiting
- Advanced Tumors
- SHR-1210
- (no location specified)
Apr 4, 2023
Recurrent or Metastatic Cervical Cancer Trial in Shanghai (SHR-1210, SHR-1020, Physician's choice chemo)
Active, not recruiting
- Recurrent or Metastatic Cervical Cancer
- SHR-1210
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Nov 14, 2022
Advanced Primary Liver Cancer, Advanced Biliary Tract Carcinoma Trial in Zhengzhou, Nanjing (SHR-1210, Apatinib, FOLFOX4)
Active, not recruiting
- Advanced Primary Liver Cancer
- Advanced Biliary Tract Carcinoma
- SHR-1210
- +3 more
-
Zhengzhou, Henan, China
- +1 more
Apr 26, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (SHR-1210)
Completed
- Nasopharyngeal Carcinoma
- SHR-1210
-
Guangzhou, Guangdong, ChinaCancer Center of Sun-Yat Sen University (CCSYSU)
Apr 1, 2022
Gastric Cancer, GastroEsophageal Cancer Trial in China (SHR-1210, Capecitabine, Oxaliplatin)
Completed
- Gastric Cancer
- GastroEsophageal Cancer
- SHR-1210
- +3 more
-
Hefei, Anhui, China
- +9 more
Jun 30, 2022
Hodgkin Lymphoma, Adult Trial in Beijing (SHR-1210)
Completed
- Hodgkin Lymphoma, Adult
- SHR-1210
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Oct 29, 2021
Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer Trial in Shanghai (SHR-1210, Famitinib)
Recruiting
- Renal Cell Carcinoma
- +4 more
- SHR-1210
- Famitinib
-
Shanghai, Shanghai, ChinaHuadong Hospital Affiliated to Fudan University
Jun 30, 2022
Gastric Cancer, GastroEsophageal Cancer Trial in Beijing (SHR-1210, Capecitabine, Oxaliplatin)
Active, not recruiting
- Gastric Cancer
- GastroEsophageal Cancer
- SHR-1210
- +3 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital, Peking University
Aug 24, 2021
Advanced Hepatocellular Carcinoma Trial in Nanjing (SHR-1210, FOLFOX4, Placebo)
Recruiting
- Advanced Hepatocellular Carcinoma
- SHR-1210
- +2 more
-
Nanjing, Jiangsu, China81 Hospital Nanjing
Feb 9, 2022
Recurrent Cervical Carcinoma, Metastatic Cervical Cancer Trial in Guangzhou, Guanzhou (SHR-1210, Apatinib)
Active, not recruiting
- Recurrent Cervical Carcinoma
- Metastatic Cervical Cancer
- SHR-1210
- Apatinib
-
Guangzhou, Guangdong, China
- +2 more
Sep 24, 2021
Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Trial in Shanghai (SHR-1210)
Not yet recruiting
- Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- SHR-1210
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Sep 5, 2021
Lung Tumors Trial in Hangzhou (SHR-1210, BP102)
Terminated
- Lung Neoplasms
- SHR-1210
- BP102
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Mar 15, 2021
Extensive Stage Small Cell Lung Cancer Trial (SHR-1210)
Not yet recruiting
- Extensive Stage Small Cell Lung Cancer
- SHR-1210
- (no location specified)
Mar 7, 2021
Resectable Esophageal Squamous Cell Carcinoma Trial (SHR-1210)
Not yet recruiting
- Resectable Esophageal Squamous Cell Carcinoma
- SHR-1210
- (no location specified)
Aug 17, 2021
Breast Cancer Trial in Guangzhou (SHR-1210, Apatinib)
Completed
- Breast Cancer
- SHR-1210
- Apatinib
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Oct 21, 2020
Esophageal Tumors, Esophageal Diseases, Esophageal Squamous Cell Carcinoma Trial in Hangzhou (Radiation, SHR-1210)
Completed
- Esophageal Neoplasms
- +2 more
- Radiation
- SHR-1210
-
Hangzhou, Zhejiang, ChinaHangzhou Cancer Hospital
Aug 13, 2020
Extranodal NK/T-cell Lymphoma, Nasal Type Trial in Zhengzhou (SHR-1210)
Unknown status
- Extranodal NK/T-cell Lymphoma, Nasal Type
- SHR-1210
-
Zhengzhou, Henan, ChinaFirst Affiliated Hospital of Zhengzhou University
Jun 17, 2020
Colorectal Cancer Trial (SHR-1210, AIN 457)
Not yet recruiting
- Colorectal Cancer
- SHR-1210
- AIN 457
- (no location specified)
Mar 12, 2020
Lung Cancer Trial in Guangzhou (SHR-1210)
Completed
- Lung Cancer
- SHR-1210
-
Guangzhou, Guangdong, ChinaCancer hospital affiliated to Zhongshan University
Apr 8, 2020
Lung Tumors, NSCLC, Respiratory Tract Tumors Trial in Shanghai (SHR-1210, Carboplatin, Pemetrexed)
Completed
- Lung Neoplasms
- +8 more
- SHR-1210
- +2 more
-
Shanghai, Shanghai, ChinaTongji University, Shanghai Pulmonary Hospital
Jun 7, 2020
Rectal Cancer Trial in Beijing (drug, radiation, procedure)
Unknown status
- Rectal Cancer
- SHR-1210
- +4 more
-
Beijing, ChinaBeijing Cancer Hospital
Jul 8, 2020
Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody Trial in China (SHR-1210, The )
Active, not recruiting
- Lung Cancer Squamous Cell
- +3 more
- SHR-1210
- The placebo
-
Hefei, Anhui, China
- +52 more
Mar 12, 2021
Non-Small-Cell Lung Cancer Trial in Jinan (SHR-1210)
Unknown status
- Non-Small-Cell Lung Cancer
- SHR-1210
-
Jinan, Shandong, ChinaShandong Cancer Hospital and Institute
Feb 3, 2020